pharmacotherapy Janus kinase inhibitor therapy 2022-08-17T19:11:56Z Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted treatment and are the first oral option to compare favourably to existing biologic disease-modifying anti-rheumatic drugs (DMARDs). Use of a drug that inhibits Janus kinases. JAK inhibitor therapy